Systematic Review on Efficacy, Effectiveness, and Safety of Pitavastatin in Dyslipidemia in Asia.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Pitavastatin effects on lipids in relation to major adverse cardiovascular events: a REPRIEVE secondary analysis.The lancet. HIV · 2026 · on this map
   Trial
2. Cost-Effectiveness Analysis of Pitavastatin in Dyslipidemia: Vietnam Case.Healthcare (Basel, Switzerland) · 2025
   Article
3. Lipid Profile and Apolipoprotein B Serum Levels in the Vietnamese Population With Newly Diagnosed Elevated Low-Density Lipoprotein Cholesterol and Association With the Single-Nucleotide Variant rs676210: Cross-Sectional Study.JMIR cardio · 2025
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

4 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as